Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Summary

This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.

Timeline

Start

2022-04-21

Primary completion

2023-12-31

Completion

2024-03-31

Publications

• Chi Y, Li Y, Cheng Q, Cai H, Zeng Y, Sheng H, Song B, Li H, Shen L, Li M, Xing Y, Cheng M, Ma Y, Wang D, Zhu M, Lu W, Yan S, Zhang X, Yuan J, Yang B, Li J, Wang J, Wu Z, Xia W. Efficacy and safety of narlumosbart, an anti-RANKL monoclonal antibody, in postmenopausal women with osteoporosis: a multi-center, randomized, double-blind, placebo- and active-controlled, phased II study. EClinicalMedicine. 2025 Jul 4;85:103329. doi: 10.1016/j.eclinm.2025.103329. eCollection 2025 Jul.

Drugs

Indications